In a recent interview with Outsourcing Pharma, Dr. Vanessa Zann, Senior Drug Development Consultant, speaks about her experience and Quotient Sciences' impact on drug development.
Dr. Zann highlights her past experience at Astra Zeneca and how she has carried that into her role at Quotient Sciences, noting the paramount importance of human data in guiding drug development decisions. She highlights case studies where Quotient Sciences has assisted in developing abuse-resistant opioid medications, notably with Ensysce Biosciences, and the role of artificial intelligence (Ai) in transforming drug development.
"AI has immense potential to streamline data analysis, predict formulation outcomes, and accelerate drug development processes. As AI continues to evolve, it promises to revolutionize pharmaceutical research and development, ushering in a new era of innovation and efficiency."
Read Delving into Quotient Science's pharma research and development on the Outsourcing Pharma website.